Why BioAtla, Inc.’s (BCAB) Stock Is Down 9.29%
As of Monday, December 01, BioAtla, Inc.’s BCAB share price has dipped by 9.29%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Commentary & Analysis
Why BioAtla, Inc.’s (BCAB) Stock Is Down 11.50%
As of Monday, December 01, BioAtla, Inc.’s BCAB share price has dipped by 11.50%, which has investors questioning if this is right time to buy.Omar Beirat
Why BioAtla, Inc.’s (BCAB) Stock Is Up 9.90%
As of Friday, November 28, BioAtla, Inc.’s BCAB share price has surged by 9.90%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why BioAtla, Inc.’s (BCAB) Stock Is Down 6.46%
As of Tuesday, November 25, BioAtla, Inc.’s BCAB share price has dipped by 6.46%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why BioAtla, Inc.’s (BCAB) Stock Is Down 10.42%
As of Tuesday, November 25, BioAtla, Inc.’s BCAB share price has dipped by 10.42%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | BCAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.4 | $227.8 | 3% |
|
| Shares Out (Mil) | 1.7 | 53.4 | 7% |
|
| Institutional Ownership | 65.6% | 92.9% | 41% |
|
| Float (Mil) | 1.4 | 41.2 | 4% |
|
| Beta | 0.76 | 0.95 | 45% |
|
| Avg Daily Volume (000s) | 6 | 513 | 15% |
|
| Price Change (52-week) |
(94.6%) | 47.3% | 4% |
|
| Growth | BCAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 38.0% | 12.8% | 93% |
|
| Net Income (5yr) | (10.7%) | (10.1%) | 28% |
|
| EPS (5yr) | 20.5% | 15.8% | 69 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.7%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BCAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $37 | 8% |
|
| Net Income (TTM) (Mil) | ($32) | ($44) | 20% |
|
| EPS (TTM) | ($22.734) | ($1.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($34) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $10 | $177 | 8% |
|
| Valuation | BCAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.22 | na |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BCAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (188.9%) | 66.9% | 1% |
|
| Net Margin | (370.0%) | (75.3%) | 3% |
|
| ROA | (171.7%) | (47.1%) | 3% |
|
| ROE | 118.7% | (53.3%) | 97% |
|
| Liabilities to Assets | 481.2% | 29.3% | 100% |
|
| F-Score | 1 | 2 | 1% |
|
BioAtla, Inc. did not pass any screens on 10/27/2026.
